Is Caribou Biosciences, Inc. (CRBU) a Buy, Sell, or Hold?
NASDAQ : CRBU
Caribou Biosciences, Inc.
$1.694 USD
-$0.04 (-2.08%)
- Volume
- 1.21M
- Average Volume
- 2.09M
- Market Capitalization
- $168.01M
- P/E Ratio
- -1.22
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $3.54
- Year Low
- $1.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.22
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Rachel E. Haurwitz |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRBU |
| CUSIP | 142038108 |
| CIK | 0001619856 |
| Web | https://cariboubio.com |
| Phone | 510 982 6030 |
| Currency | USD |
| Employees | 97 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.26 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.22 |
| Quick Ratio | 6.22 |
| Cash Ratio | 0.61 |
Sales & Book Value
| Annual Sales | $11.16M |
| Price / Sales | 15.32 |
| Cash Flow | -1.06 |
| Price / Cash Flow | -1.69 |
| Price / Book | 1.63 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -66.12% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.59 |
| Trailing P/E Ratio | -1.22 |
| PEG Ratio | -0.11 |
| P/E Growth | -0.11 |
| Net Income | -$148.12M |
| Net Margin | -1189.14% |
| Pretax Margin | -1194.05% |
| Return on Equity | -100.13% |
| Return on Assets | -89.41% |
Financials Score
| AltmanZ Score | -5.30 |
| Piotroski Score | 3.00 |
| Working Capital | 102.71M |
| Total Assets | 149M |
| Ebit | -115.1M |
| Market Cap | 171.58M |
| Total Liabilities | 46.98M |
Poll Results
About Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an ... allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
2026-07-09 10:41:40
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-29 08:00:00
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the H.C.
2026-06-11 08:01:00
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --
2026-06-11 08:00:00
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient who previously received an anti-BCMA CAR-T showed an early complete response that was ongoing as of the data cutoff date -- -- EHA oral presentation scheduled for Sunday, June 14, 2026, at 11:00am CEST -- -- CaMMouflage phase 1 initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 -- BERKELEY, Calif.
2026-06-11 08:00:00
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient who previously received an anti-BCMA CAR-T showed an early complete response that was ongoing as of the data cutoff date --
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
2026-06-09 06:06:02
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-05 16:52:53
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 16:05:00
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York.
Frequently Asked Questions
-
What is the current Caribou Biosciences, Inc. (CRBU) stock price?
-
Caribou Biosciences, Inc.(NASDAQ:CRBU) stock price is $1.694 in the last trading session. During the trading session, CRBU stock reached the peak price of $3.535 while $1.38 was the lowest point it dropped to. The percentage change in CRBU stock occurred in the recent session was --2.08% while the dollar amount for the price change in CRBU stock was -$0.04.
-
CRBU's industry and sector of operation?
-
The NASDAQ listed CRBU is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRBU?
-
Barbara G. McClung | Chief Legal Officer & Corporate Secretary
Jennifer A. Doudna | Co-founder & Member of Scientific Advisory Board
Ryan Fischesser | Interim Principal Accounting Officer & Controller
Reigin Zawadzki | Chief People Officer
Ruhi A. Khan | Chief Business Officer -
How many employees does CRBU have?
-
Number of CRBU employees currently stands at 97. CRBU operates from 2929 7th Street, Berkeley, CA 94710, US.
-
Link for CRBU official website?
-
Official Website of CRBU is: https://cariboubio.com
-
How do I contact CRBU?
-
CRBU could be contacted at phone #510 982 6030 and can also be accessed through its website. CRBU operates from 2929 7th Street, Berkeley, CA 94710, US.
-
How many shares of CRBU are traded daily?
-
The average number of CRBU shares traded daily for last 3 months was 2.09M.
-
What is the market cap of CRBU currently?
-
The market value of CRBU currently stands at $168.01M with its latest stock price at $1.694